Wang Yingqian, Ma Zeqiang, Jiang Lehua, Bojan Nataraj, Sha Yiwen, Huang Boyu, Ming Lianxi, Shen Junnan, Pang Weijun
Laboratory of Animal Fat Deposition and Muscle Development, College of Animal Science and Technology, Northwest A&F University, Shaanxi, China.
Center for Metabolic & Gastroenterology, Institute of Translational Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
J Nanobiotechnology. 2025 Mar 3;23(1):159. doi: 10.1186/s12951-025-03225-0.
Skeletal muscle lipid deposition is a key manifestation of obesity, often accompanied by decreased exercise capacity and muscle atrophy. Skeletal muscle as the largest organ in the body, makes it challenges for designing targeted drug delivery systems. Lipid nanoparticles (LNPs) are widely used as a safe and efficient delivery carrier, there is limited research on LNPs that specifically target skeletal muscle.
A LNP designed with five specific receptor complements on its surface, which specifically targets skeletal muscle in vivo in mice, without off-target effects on other tissues and organs. MiR-130a, a regulator of PPARG, which is a key factor in skeletal muscle lipid deposition, was encapsulated with LNP (LNP@miR-130a). In high-fat diet (HFD) mice, LNP@miR-130a effectively reduced skeletal muscle lipid deposition, increased exercise activity and enhanced muscle mass. Interestingly, the myokines in skeletal muscle have also changed which may leading to reduce the adipose tissue weight and liver lipid deposition in HFD mice.
These results indicated LNP@miR-130a is a promising inhibitor of skeletal muscle lipid deposition and may help alleviate obesity. This study provides new insights for obesity treatment and lays foundation for the development of targeted skeletal muscle therapeutics.
骨骼肌脂质沉积是肥胖的关键表现,常伴有运动能力下降和肌肉萎缩。骨骼肌作为人体最大的器官,给设计靶向给药系统带来了挑战。脂质纳米颗粒(LNPs)作为一种安全有效的递送载体被广泛应用,但针对骨骼肌的特异性LNPs研究有限。
设计了一种表面带有五种特异性受体配体的LNP,其在小鼠体内可特异性靶向骨骼肌,对其他组织器官无脱靶效应。将PPARG的调节因子MiR-130a(PPARG是骨骼肌脂质沉积的关键因子)用LNP包裹(LNP@miR-130a)。在高脂饮食(HFD)小鼠中,LNP@miR-130a有效减少了骨骼肌脂质沉积,增加了运动活性并增强了肌肉质量。有趣的是,骨骼肌中的肌动蛋白也发生了变化,这可能导致HFD小鼠的脂肪组织重量减轻和肝脏脂质沉积减少。
这些结果表明LNP@miR-130a是一种有前景的骨骼肌脂质沉积抑制剂,可能有助于减轻肥胖。本研究为肥胖治疗提供了新的见解,并为靶向骨骼肌治疗药物的开发奠定了基础。